Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001274173-25-000125
Filing Date
2025-05-14
Accepted
2025-05-14 11:48:48
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 7512
  Complete submission text file 0001274173-25-000125.txt   9619
Mailing Address 201 BISHOPSGATE LONDON X0 EC2M 3AE
Business Address 201 BISHOPSGATE LONDON X0 EC2M 3AE 442078181818
JANUS HENDERSON GROUP PLC (Filed by) CIK: 0001274173 (see all company filings)

EIN.: 000000000 | State of Incorp.: Y9 | Fiscal Year End: 1231
Type: SCHEDULE 13G
SIC: 6282 Investment Advice
(CF Office: 02 Finance)

Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Subject) CIK: 0001438533 (see all company filings)

EIN.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-87088 | Film No.: 25943766
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)